Welcome to our dedicated page for Bioharvest news (Ticker: BHST), a resource for investors and traders seeking the latest updates and insights on Bioharvest stock.
BioHarvest Sciences Inc. (NASDAQ: BHST) is a biotechnology company that describes itself as a leader in Botanical Synthesis, using its patented plant cell-based platform to grow active plant compounds without cultivating the whole plant. The BioHarvest news stream highlights how this technology underpins both its direct-to-consumer nutraceutical products and its contract development and manufacturing (CDMO) services.
Investors following BHST news can read about developments in the company’s VINIA brand, including capsules, hot beverages, daily chews, and VINIA Blood Flow Hydration, which the company presents as a hydration solution powered by the blood flow benefits of Piceid resveratrol. News items also cover subscriber trends, online channel performance, and the expansion of VINIA into broader health and wellness categories.
Another major theme in BioHarvest’s news is the evolution of its CDMO Services division. Company updates describe new customer contracts in pharmaceuticals, nutrition, fragrance, and nutraceuticals, such as a saffron-derived compound partnership with Saffron Tech and work on a plant-based fragrance compound. Releases also discuss milestones like producing plant-based exosomes at scale in a bioreactor and integrating AI-based tools into a second-generation Botanical Synthesis process.
Capital markets and regulatory announcements form a further part of the BHST news flow, including public offerings under a Form F-3 shelf registration, material change reports, and interim financial results filed on Form 6-K. Readers can use this page to monitor BioHarvest’s operational updates, technology progress, and financing activities in one place.
BioHarvest Sciences (NASDAQ:BHST) has significantly strengthened its financial position through a series of transactions totaling $14.7 million in balance sheet improvements. The biotechnology company secured $10.9 million in gross proceeds through warrant exercises and convertible note issuances, while simultaneously reducing debt by $3.8 million.
The transactions included $5.8 million raised through warrant exercises, $5.1 million from new convertible notes, and various debt conversions and repayments. The company offered warrant holders and convertible loan holders a reduced price of $6.50 per share. Following these transactions, BioHarvest's total debt stands at $6.6 million.
The proceeds will fund capital expenditures for new capacity building, debt refinancing, and working capital requirements.
BioHarvest Sciences (NASDAQ: BHST) has achieved a significant breakthrough in its Botanical Synthesis platform by successfully producing plant-based exosomes at scale in its bioreactor media. These nano-sized vesicles, naturally secreted by plant cells, offer enhanced absorption and bioavailability compared to regular plant compounds.
The company's bioreactors, which combine optimized growth media with light-permeable technology, produce exosomes containing viniferin, a polyphenol valued for skincare applications. This development positions BioHarvest to enter the global exosome market, projected to grow from $0.7B in 2025 to $2.2B by 2030. The company expects to launch a new skincare application within 18-24 months.
BioHarvest Sciences (NASDAQ: BHST) has announced an upcoming Virtual Investor Webinar scheduled for September 10, 2025, at 1:00 PM ET. CEO Ilan Sobel will lead the presentation, focusing on new capability-building initiatives and the company's strategic 'Big Bets' for the second half of 2025.
The webinar will cover updates on both consumer and CDMO business units, including progress on the Health Pros program, hydration product development, and key CDMO efforts. Participants can join via phone or webcast, with playback available through September 24, 2025.
BioHarvest Sciences (NASDAQ: BHST) reported strong Q2 2025 financial results with revenue growing 41% year-over-year to $8.5 million and gross margins expanding to 60%. The company's VINIA® product line continues to perform well, with 65,000 active U.S. users and over $60 million in cumulative revenue since its 2021 launch.
Key developments include securing new CDMO contracts, launching VINIA® Daily Chews 2X Formula, and advancing three growth initiatives: a Health Pros affiliate program, entry into the electrolyte drinks market, and an AI-enabled CDMO discovery service. Management expects Q3 2025 revenues of at least $9.1 million and projects reaching adjusted EBITDA breakeven in Q4 2025.
BioHarvest Sciences (NASDAQ: BHST), a pioneer in Botanical Synthesis technology, has scheduled its Q2 2025 earnings conference call for August 11, 2025, at 8:00 a.m. Eastern Time. The company will release its financial results for the quarter ended June 30, 2025, before the market opens.
The conference call will include a corporate update and a Q&A session. Participants can join via U.S./Canada dial-in (1-877-300-8521) or International dial-in (1-412-317-6026) using Conference ID 0083058. A replay will be available through August 25, 2025, and can be accessed via webcast or telephone playback.
BioHarvest Sciences (NASDAQ: BHST), a pioneer in Botanical Synthesis technology, will present at the Canaccord Genuity 45th Annual Growth Conference from August 12-14, 2025, in Boston, Massachusetts.
CEO Ilan Sobel will conduct one-on-one meetings with institutional investors and deliver a corporate presentation on Tuesday, August 12, 2025, at 11:00 a.m. Eastern time at the InterContinental Boston Hotel. The presentation will highlight the company's growth momentum across its consumer and CDMO businesses.
BioHarvest Sciences Inc. (NASDAQ: BHST) has secured a new CDMO (Contract Development and Manufacturing Organization) contract to develop a plant-based fragrance compound from a threatened plant species. The company will utilize its Botanical Synthesis technology platform and AI-assisted research capabilities for this project targeting the multi-billion-dollar fragrance market.
The Stage 1 contract focuses on developing cell banks for future production of targeted fragrance molecules, with milestone-based payments. Upon successful completion, Stage 2 would involve compound production in liquid media. This agreement expands BioHarvest's CDMO portfolio beyond pharmaceuticals and nutrition into the fragrance industry while contributing to rare plant species conservation.
BioHarvest Sciences (NASDAQ: BHST) has successfully completed Stage 1 of its CDMO contract with an unnamed Nasdaq-listed pharmaceutical company and is advancing to Stage 2. The project, which began in early 2024, demonstrates the capability of BioHarvest's Botanical Synthesis platform to develop active pharmaceutical compounds.
In Stage 1, BioHarvest's research team successfully isolated target plant cells and replicated them using their proprietary platform. Stage 2 will focus on producing sufficient biomass for testing and developing optimal growing conditions in liquid media. Upon success, the project will progress to small and medium-scale production before moving to commercial volume production.
This milestone validates the platform's versatility and positions BioHarvest as a trusted partner in providing scalable, cost-effective alternatives to traditional compound sourcing for pharmaceutical, nutrition, and nutraceutical industries.FAQ
What is the current stock price of Bioharvest (BHST)?
What is the market cap of Bioharvest (BHST)?
